Ventilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges.

Fiona Howroyd; Cyril Chacko; Andrew MacDuff; Nandan Gautam; Brian Pouchet; Bill Tunnicliffe; Jonathan Weblin; Fang Gao Smith; Zubair Ahmed; Niharika Duggal; Tonny Veenith

doi:10.1038/s41467-024-50805-z

Ventilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges.

Fiona Howroyd^*, Cyril Chacko, Andrew MacDuff, Nandan Gautam, Brian Pouchet, Bill Tunnicliffe, Jonathan Weblin, Fang Gao Smith, Zubair Ahmed^*, Niharika Duggal^*, Tonny Veenith^*

^*Corresponding author for this work

Inflammation and Ageing

Research output: Contribution to journal › Review article › peer-review

64 Downloads (Pure)

Abstract

Ventilator-associated pneumonia (VAP) affects up to 20% of critically ill patients and induces significant antibiotic prescription pressure, accounting for half of all antibiotic use in the ICU. VAP significantly increases hospital length of stay and healthcare costs yet is also associated with long-term morbidity and mortality. The diagnosis of VAP continues to present challenges and pitfalls for the currently available clinical, radiological and microbiological diagnostic armamentarium. Biomarkers and artificial intelligence offer an innovative potential direction for ongoing future research. In this Review, we summarise the pathobiological heterogeneity and diagnostic challenges associated with VAP.

Original language	English
Article number	6447
Number of pages	13
Journal	Nature Communications
Volume	15
DOIs	https://doi.org/10.1038/s41467-024-50805-z
Publication status	Published - 31 Jul 2024

Access to Document

10.1038/s41467-024-50805-zLicence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

HowroydF2024VentilatorFinal published version, 1.34 MBLicence: Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Cite this

@article{e9f369beb9cf48759d0db2b81974279d,

title = "Ventilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges.",

abstract = "Ventilator-associated pneumonia (VAP) affects up to 20% of critically ill patients and induces significant antibiotic prescription pressure, accounting for half of all antibiotic use in the ICU. VAP significantly increases hospital length of stay and healthcare costs yet is also associated with long-term morbidity and mortality. The diagnosis of VAP continues to present challenges and pitfalls for the currently available clinical, radiological and microbiological diagnostic armamentarium. Biomarkers and artificial intelligence offer an innovative potential direction for ongoing future research. In this Review, we summarise the pathobiological heterogeneity and diagnostic challenges associated with VAP.",

author = "Fiona Howroyd and Cyril Chacko and Andrew MacDuff and Nandan Gautam and Brian Pouchet and Bill Tunnicliffe and Jonathan Weblin and {Gao Smith}, Fang and Zubair Ahmed and Niharika Duggal and Tonny Veenith",

year = "2024",

month = jul,

day = "31",

doi = "10.1038/s41467-024-50805-z",

language = "English",

volume = "15",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Springer",

}

TY - JOUR

T1 - Ventilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges.

AU - Howroyd, Fiona

AU - Chacko, Cyril

AU - MacDuff, Andrew

AU - Gautam, Nandan

AU - Pouchet, Brian

AU - Tunnicliffe, Bill

AU - Weblin, Jonathan

AU - Gao Smith, Fang

AU - Ahmed, Zubair

AU - Duggal, Niharika

AU - Veenith, Tonny

PY - 2024/7/31

Y1 - 2024/7/31

N2 - Ventilator-associated pneumonia (VAP) affects up to 20% of critically ill patients and induces significant antibiotic prescription pressure, accounting for half of all antibiotic use in the ICU. VAP significantly increases hospital length of stay and healthcare costs yet is also associated with long-term morbidity and mortality. The diagnosis of VAP continues to present challenges and pitfalls for the currently available clinical, radiological and microbiological diagnostic armamentarium. Biomarkers and artificial intelligence offer an innovative potential direction for ongoing future research. In this Review, we summarise the pathobiological heterogeneity and diagnostic challenges associated with VAP.

AB - Ventilator-associated pneumonia (VAP) affects up to 20% of critically ill patients and induces significant antibiotic prescription pressure, accounting for half of all antibiotic use in the ICU. VAP significantly increases hospital length of stay and healthcare costs yet is also associated with long-term morbidity and mortality. The diagnosis of VAP continues to present challenges and pitfalls for the currently available clinical, radiological and microbiological diagnostic armamentarium. Biomarkers and artificial intelligence offer an innovative potential direction for ongoing future research. In this Review, we summarise the pathobiological heterogeneity and diagnostic challenges associated with VAP.

U2 - 10.1038/s41467-024-50805-z

DO - 10.1038/s41467-024-50805-z

M3 - Review article

SN - 2041-1723

VL - 15

JO - Nature Communications

JF - Nature Communications

M1 - 6447

ER -

Ventilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges.

Abstract

Access to Document

Fingerprint

Cite this